Skip to main content
Home
  • ALL Specialities ALL Specialities
    Home
    Home

    Caleb Rans

    News

    Past donor pregnancy, sex do not affect transfusion-related mortality

    Author:
    Caleb Rans
    Publish date: June 11, 2019

    A retrospective analysis of more than 1 million red blood cell transfusion recipients found that there was no significant increase in mortality...

    • Read More

    News

    ASCO clinical practice guideline update incorporates Oncotype DX

    Author:
    Caleb Rans
    Publish date: June 4, 2019

    In women with hormone receptor–positive, axillary node–negative breast cancer with Oncotype DX recurrence scores of less than 26, there is minimal...

    • Read More

    News

    NCCN publishes pediatric ALL guidelines

    Author:
    Caleb Rans
    Publish date: June 3, 2019

    While treatment for ALL often includes long-term chemotherapy regimens, various types of immunotherapy and targeted therapy are also summarized in...

    • Read More

    News

    Cediranib may alter DNA repair capacity

    Author:
    Caleb Rans
    Publish date: June 3, 2019

    The preclinical finding may have implications for the development of combination treatment with olaparib for cancer patients.

    • Read More

    News

    Novel anti-PD-1 antibody can be given subcutaneously

    Author:
    Caleb Rans
    Publish date: May 31, 2019

    “Subcutaneous administration of an anti-PD-1 antibody in patients with advanced solid tumors appears to be feasible,” the investigators wrote.

    • Read More

    News

    Revascularization plus exercise is most effective for intermittent claudication

    Author:
    Caleb Rans
    Publish date: May 29, 2019

    Percutaneous transluminal angioplasty plus supervised treadmill exercise therapy could be a first-line treatment...

    • Read More

    News

    Genetic analysis identifies prognostic markers in CLL

    Author:
    Caleb Rans
    Publish date: May 28, 2019

    A single 11q22 deletion, lacking an ATM mutation on the other allele, had the shortest progression-free survival among patients with CLL who were...

    • Read More

    News

    FVIII/W ratio may help predict relapse in hemophilia A

    Author:
    Caleb Rans
    Publish date: May 22, 2019

    The biological marker was the first indication of relapse in most patients who relapsed during the study period.

    • Read More

    News

    Novel chromogenic assay looks accurate in hemophilia A diagnosis

    Author:
    Caleb Rans
    Publish date: May 22, 2019

    The BIOPHEN FVIII:C assay had limited variation and performed well when compared with a one-stage clotting assay and another chromogenic assay,...

    • Read More

    News

    Low-dose FVIII prophylaxis reduced bleeding in hemophilia A

    Author:
    Caleb Rans
    Publish date: May 22, 2019

    Low-dose prophylaxis with factor VIII outperformed on-demand treatment in children with severe hemophilia A. The findings have implications for...

    • Read More

    News

    Family history plays a large role in bleeding disorder diagnosis in women

    Author:
    Caleb Rans
    Publish date: May 17, 2019

    The survey of women with congenital bleeding disorders in Europe highlighted delays in diagnosis and burdens on activities of daily living.

    • Read More

    News

    CD23 expression linked to improved survival in MCL

    Author:
    Caleb Rans
    Publish date: May 17, 2019

    Researchers found that mantle cell lymphoma cases that were CD23 positive had a higher frequency of leukemic nonnodal presentation and CD200...

    • Read More

    News

    Literature review shows inconsistent measurement of financial toxicity

    Author:
    Caleb Rans
    Publish date: May 16, 2019

    Systematic review reveals lack of validated instruments to effectively measure the financial burden experienced by cancer patients.

    • Read More

    News

    Younger patients with NSCLC tend to live longer

    Author:
    Caleb Rans
    Publish date: May 15, 2019

    According to a retrospective analysis, younger patients with NSCLC had better survival, despite higher rates of brain metastasis and drive...

    • Read More

    News

    Most postapproval trials explore novel indications

    Author:
    Caleb Rans
    Publish date: May 10, 2019

    Among 600 post-approval studies, only 12.0% solely examined the original therapeutic indication.

    • Read More

    Pages

    • « first
    • …
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • 11
    • 12
    • last »

    Privacy Policy

    Terms of Use

    Editorial Policy

    Cookie Policy

    Ad Policy

    Medscape Customer Support

    Frequently Asked Questions

     

    Advertise with MDedge

    See more with MDedge! See our Other Publications

    MDedge: Keeping You Informed. Saving You Time.

    Copyright  © 2024 Frontline Medical Communications Inc., 283-299 Market Street, 2 Gateway Center, 4th Floor, Newark, NJ 07102. All rights reserved. Unauthorized use prohibited. The information provided is for educational purposes only. Use of this Web site is subject to the medical disclaimer.

    • All Specialties
      • MDedge Home
      • Cardiology
      • Clinician Reviews
      • Dermatology
      • Emergency Medicine
      • Endocrinology/Diabetes
      • Family Medicine
      • Federal Practitioner
      • Gastroenterology
      • Hematology/Oncology
      • Infectious Disease
      • Internal Medicine
      • Neurology
      • Obstetrics And Gynecology
      • Pediatrics
      • Psychiatry
      • Pulmonology
      • Rheumatology
      • Surgery
    • MDedge Home
    • Cardiology
    • Clinician Reviews
    • Dermatology
    • Emergency Medicine
    • Endocrinology/Diabetes
    • Family Medicine
    • Federal Practitioner
    • Gastroenterology
    • Hematology/Oncology
    • Infectious Disease
    • Internal Medicine
    • Neurology
    • Obstetrics And Gynecology
    • Pediatrics
    • Psychiatry
    • Pulmonology
    • Rheumatology
    • Surgery